Why the diagnosis must be specific
Type 2 diabetes differs from type 1 diabetes, latent autoimmune diabetes, pancreatogenic diabetes and other forms. Misclassification changes the relevance of any cell-based pathway.
The diagnosis alone is not enough. Duration, C-peptide, insulin use, body weight, medication, kidney function and complications affect the clinical question.
What a regenerative pathway may involve
RMC has not verified a current clinical authorisation or international intake for a UC-MSC proposal for type 2 diabetes. Ask for the exact product, indication and legal route; a public programme description cannot substitute for those documents.
Records needed for a meaningful review
- HbA1c and recent glucose data
- C-peptide and insulin when available
- Current medications and doses
- Insulin regimen and glucose monitoring
- Kidney and liver function
- BMI and weight trend
- Retinopathy, neuropathy, vascular and foot complications
- Ketoacidosis or severe hypoglycaemia history
The reviewing institution may request additional tests after seeing the initial case summary.
Questions that affect eligibility
- Is the diabetes classification correct?
- How much endogenous insulin production remains?
- Are glucose levels stable enough for elective care?
- What organ complications exist?
- What standard therapies have been tried?
- What outcome is realistic and measurable?
Evidence and limitations
MSC-based strategies and beta-cell replacement research are different. Evidence should be reviewed for the exact product and diabetes type. A broad claim that “stem cells cure diabetes” is not an adequate medical explanation.
Other treatment options to consider
Nutrition, exercise, weight management, glucose monitoring and evidence-based medication — including therapies with cardiovascular or kidney benefit — remain important. Endocrinology review may identify standard options that have not been fully used.
Next step for an international patient
Send diabetes type, duration, HbA1c, C-peptide if available, current medication, insulin use and major complications.
Do not stop prescribed treatment, make irreversible travel plans or pay a medical fee until the responsible institution has reviewed the case and issued written instructions.